ReviewBlood2018
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Review in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04181489 (A Phase II, Prospective, Multi-center Study of Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS), which is not on this map. Cited by 279 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II, Prospective, Multi-center Study of Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS
Who cites it
279 citing papers in PubMed, 4 syntheses or guidelines pooled it, 425 citations in OpenAlex.
- Umbrella Systematic Review of the Efficacy and Safety of PD-1 Inhibitors Combined with CTLA-4 Inhibitors in the Treatment of Melanoma.International journal of molecular sciences · 2026Pooled it
- Pooled it
- A Large-Scale Meta-Analysis Reveals Positive Feedback between Macrophages and T Cells That Sensitizes Tumors to Immunotherapy.Cancer research · 2024Pooled it
- Pooled it
- Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.Nature medicine · 2024Trial
- Research progress on the molecular mechanisms of PD-1 and LAG-3 synergy in regulating T cell exhaustion and immunotherapy.Annals of medicine · 2026Review
- Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.Blood advances · 2026Article
- Is There a Tumor Proportion Score Threshold at Which Tumor-Cell PD-L1 Adds Prognostic Information Beyond the International Prognostic Index in Large B-Cell Lymphoma?Diagnostics (Basel, Switzerland) · 2026Article
- Immune checkpoints and immunoregulation in metabolic diseases and cancers: pathological mechanisms and therapeutic potential.Signal transduction and targeted therapy · 2026Review
- Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Single-cell and spatial transcriptomic profiling of POU5F1 in Lung Adenocarcinoma: Dynamics, spatial niche, and prognosis via multi-algorithm ML.Translational oncology · 2026Article
- Review
- Diffuse Large B-Cell Lymphoma: From Molecular Stratification to Precision Immunotherapy.Cells · 2026Review
- Microchromosome maintenance protein 2 is essential in immune infiltration-correlated prognosis of multiple myeloma patients by regulating cell cycle.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Safety and effectiveness of lisocabtagene maraleucel following PD-1 blockade in relapsed or refractory PMBCL.International journal of hematology · 2026Article
- synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapy.Cancer immunology, immunotherapy : CII · 2026Article
- Phenotypic Characterization and Prognostic Impact of CD103+ Tissue-Resident Memory T Cells in Diffuse Large B-cell Lymphoma.Cancer immunology research · 2026Article
- Paroxetine repurposing enhances antitumor immunity via SPOP-mediated PD-L1 ubiquitination and proteasomal degradation.Journal of experimental & clinical cancer research : CR · 2026Article
- Novel immunotherapeutic strategies for diffuse large B-cell lymphoma: a comprehensive review.Frontiers in immunology · 2026Review
- CD47 Expression in Classic Hodgkin Lymphoma and Its Association With Tumor Microenvironment.Journal of immunology research · 2026Article
219 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Programmed cell death protein 1 (PD-1) blockade targeting the PD-1 immune checkpoint has demonstrated unprecedented clinical efficacy in the treatment of advanced cancers including hematologic malignancies. This article reviews the landscape of PD-1/programmed death-ligand 1 (PD-L1) expression and current PD-1 blockade immunotherapy trials in B-cell lymphomas. Most notably, in relapsed/refractory classical Hodgkin lymphoma, which frequently has increased PD-1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.